Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

CD63 Antibodies

CD63, a member of the tetraspanin protein family, plays a crucial role in cellular processes, particularly in membrane organization and trafficking. With a molecular weight of approximately 30 kDa, CD63 is primarily expressed intracellularly within endosomes and lysosomes and is later incorporated into the cell membrane. Posttranslational modifications, such as glycosylation and palmitoylation, contribute to the diversity of CD63’s functions and interactions.

The fundamental function of CD63 is to participate in forming tetraspanin-enriched microdomains on cell membranes. These microdomains, known as tetraspanin webs, play a role in cell adhesion, migration, and intracellular signaling. CD63 is expressed in various cell types, including immune (e.g., platelets, mast cells), endothelial, and reproductive system cells. It is particularly abundant in late endosomes and lysosomes, contributing to vesicle trafficking and fusion processes.

The expression of CD63 is modulated in response to cellular activation, inflammation, and various physiological stimuli. It is involved in diverse cellular functions, ranging from platelet activation and granule secretion to antigen presentation in immune cells. In human health and disease, CD63 has been implicated in various pathological conditions, including cancer, infectious diseases, and inflammatory disorders. Its role in cancer metastasis, where it facilitates the release of exosomes containing cancer-promoting molecules, underscores its significance in disease progression.

Antibodies targeting CD63 have wide-ranging applications in research, diagnostics, and therapeutic development. In research, CD63 antibodies are utilized for techniques such as flow cytometry, immunofluorescence, and Western blotting to analyze CD63 expression, localization, and interactions. In diagnostics, CD63 is considered a potential biomarker for certain cancers, and CD63 antibodies are employed for immunohistochemical analyses of tumor tissues. Therapeutically, CD63 is being explored as a target for cancer therapy, and CD63 antibodies are investigated for their potential in immunotherapy and targeted drug delivery.

Neobiotechnologies is committed to providing high-quality antibodies for researchers and clinicians studying CD63 and its implications in health and disease. Explore our extensive catalog to access reliable tools for studying CD63 and contribute to cancer research, immunology, and therapeutic development advancements. Elevate your research capabilities with our cutting-edge antibodies and support the quest for improved diagnostics and targeted therapeutics.


CD63 antigen, Granulophysin, Lysosomal-associated membrane protein 3, Lysosome integral membrane protein 1, Melanoma-associated antigen ME491, OMA81H, Ocular melanoma-associated antigen, Tetraspanin-30, gp55; granulophysin; Lysosomal-associated membrane protein 3 (LAMP-3); Mast cell antigen AD1; Melanoma-associated antigen MLA1; Melanoma-associated antigen ME491; NGA; Ocular melanoma-associated antigen; OMA81H; Tetraspanin-30; TSPAN30

Research Areas


Showing 1–25 of 33 results


Showing 1–25 of 33 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.